Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/ G724S Mutation

被引：0
|
作者：
Lyu, X. [1 ]
Jiao, T. [1 ]
Yang, S. [1 ]
Yang, S. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
lung adenocarcinoma; targeted therapy; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-08
引用
收藏
页码：S643 / S643
页数：1
相关论文
共 50 条
  • [21] KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR
    Yamaoka, Toshimitsu
    Motoi, Ohba
    Kishino, Yasunari
    Kusumoto, Sojiro
    Tsurutani, Junji
    Ohmori, Tohru
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation
    Ma, W.
    Gong, J.
    Shan, J.
    Lewis, D.
    Xiao, W.
    Hung, J.
    Moore, E. H.
    Zhang, Y.
    Mans, N. Z.
    Welborn, J.
    Lam, K. S.
    Li, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1863 - S1864
  • [23] KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
    Nakatani, Kaori
    Yamaoka, Toshimitsu
    Ohba, Motoi
    Fujita, Ken-Ichi
    Arata, Satoru
    Kusumoto, Sojiro
    Taki-Takemoto, Iori
    Kamei, Daisuke
    Iwai, Shinichi
    Tsurutani, Junji
    Ohmori, Tohru
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 112 - 126
  • [24] Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
    Buzard, Blake
    Douglass, Lindsey
    Gustafson, Beth
    Buckley, Jennifer
    Roth, Marc
    Kujtan, Lara
    Bansal, Dhruv
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (10) : 1829 - 1834
  • [25] Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC
    van Kempen, Leon C.
    Wang, Hangjun
    Aguirre, Maria Leonor
    Spatz, Alan
    Kasymjanova, Goulnar
    Vilacha, Juliana F.
    Groves, Matthew R.
    Agulnik, Jason
    Small, David
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : E161 - E163
  • [26] Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation
    Horiuchi, Kohei
    Asakura, Takanori
    Sakaguchi, Shinji
    Saito, Fumitake
    BMJ CASE REPORTS, 2019, 12 (06)
  • [27] Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient with EGFR TKI Drug Resistance
    Xu, S.
    Liu, X.
    Liu, R.
    Shi, T.
    Li, X.
    Zhong, D.
    Wang, Y.
    Chen, G.
    Chen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2201 - S2201
  • [28] Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
    Macerola, Elisabetta
    Bruno, Rossella
    Prediletto, Irene
    Sensi, Elisa
    Chella, Antonio
    Landi, Lorenza
    Ali, Greta
    Fontanini, Gabriella
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1207 - S1207
  • [29] De novo EGFR T790M mutation in lung cancer patients harboring sensitive EGFR mutations
    Lee, Youngjoo
    Lee, Geon Kook
    Lee, Yeon-Su
    Zhang, Wenji
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Predictive Factors of Osimertinib as Salvage Treatment for Metastatic EGFR T790M Positive Lung Adenocarcinoma
    Jang, S. H.
    Park, J. Y.
    Hwang, Y. I.
    Kim, H. Y.
    Seo, J. W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S830 - S830
12345